Date published: 2026-8-31

1-800-457-3801

SCBT Portrait Logo
Seach Input

ARK-3 CRISPR/Cas9 KO Plasmid (m): sc-423193

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: mouse
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • ARK-3 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
  • gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the ARK-3 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
  • The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    ARK-3 CRISPR/Cas9 KO Plasmid (m)

    sc-423193
    20 µg
    $397.00

    Overview

    Aurkc encodes Aurora kinase C (ARK-3), a serine/threonine kinase that regulates chromosome dynamics and cell division through phosphorylation of mitotic substrates involved in centrosome function, spindle assembly, and cytokinesis. In mouse germ cells, AURKC activity is particularly important for meiotic progression and accurate chromosomal segregation, intersecting with core mitotic regulatory networks that coordinate kinetochore–microtubule attachments and the spindle checkpoint. Dysregulation of Aurora kinase signaling is linked to aneuploidy and genomic instability, processes that are frequently studied in reproductive biology, developmental genetics, and cancer-relevant cell cycle models. Aurkc perturbation therefore provides a useful entry point for dissecting mechanisms of chromosome mis-segregation and cell cycle control.

    ARK-3 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Aurkc gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Aurkc together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

    The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Aurkc open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish ARK-3 protein expression.

    This CRISPR knockout system enables efficient generation of Aurkc-deficient cell models for investigation of ARK-3 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

    Key Features

    • sgRNAs targeting Aurkc exon(s) critical for ARK-3 function
    • Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
    • GFP reporter for identification of transfected cells
    • Pool of plasmids targeting multiple Aurkc genomic sites to improve knockout efficiency
    • Compatible with delivery by transfection

    Design Variants

    CRISPRs +/- HDRs

    • gRNAs encoded by ARK-3 CRISPR/Cas9 KO Plasmid (m) and ARK-3 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Aurkc locus. One or both targeting designs may be available. See Related Products for availability.
    • HDR donor constructs encoded by ARK-3 HDR Plasmid (m) and ARK-3 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Aurkc homology arms to support homology-directed repair at defined Aurkc target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.